RxDoctor Payments Data

Deepak Tikku, MD

Neurology · Debary, FLNPI 1689748345

Payments from drug & device makers

$2,527in general payments, 2019–2025

Across 138 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$895
  • Sunovion Pharmaceuticals Inc.$269
  • Sanofi$230
  • Teva Pharmaceuticals USA, Inc.$137
  • AstraZeneca$107
  • Otsuka America Pharmaceutical, Inc.$101
  • plus $787 from 16 others

What the payments were for

  • Food & beverage$2,47798%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,527 in reported general payments places this provider in the 50th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$80,351
Medicare patients
316
Services billed
5,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab45$419,068
MysolinePrimidone14$128,369
Emgality PenGalcanezumab-Gnlm140$117,629
Avonex Pen (4 Pack)Interferon Beta-1a14$108,048
VumerityDiroximel Fumarate12$103,600
BotoxOnabotulinumtoxina48$59,409
UbrelvyUbrogepant32$45,790
QuliptaAtogepant25$39,559
Aimovig AutoinjectorErenumab-Aooe44$33,690
Lacosamide151$19,501
Memantine Hcl536$13,808
NayzilamMidazolam21$13,799
Levetiracetam329$13,578
Oxcarbazepine115$10,689
TegretolCarbamazepine22$10,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$895$144,758105 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$60$8,65113 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$16$5,58349 claims
PfizerDilantin$33$2,82214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,434 neurology providers in Florida.

Other neurology in Debary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →